Merck's Keytruda nabs new data to rival Bristol-Myers' Opdivo at fending off melanoma's return
admin 15th January 2018 Uncategorised 0Merck & Co. and Bristol-Myers Squibb have been head-to-head competitors in melanoma ever since their two immuno-oncology treatments, Keytruda and Opdivo, both won their first FDA approvals. Now, with its latest data, Keytruda can play catch-up with its rival for another new use.
More: Merck's Keytruda nabs new data to rival Bristol-Myers' Opdivo at fending off melanoma's return
Source: fierce